Novo Nordisk haemophilia drug moves closer to approval in Japan
COPENHAGEN Nov 18 (Reuters) - NovoEight, a haemophilia drug made by Denmark's Novo Nordisk, is a step closer to marketing approval in Japan after it passed a review by the country's drugs committee.
Novo, the world's biggest insulin producer, said in a statement on Monday that it expects to receive marketing authorisation within a few months.
The remaining step in the regulatory process is an official approval from the Ministry of Health, Labour and Welfare, to which the Committee on Drugs serves as an advisory body. (Reporting by Mette Fraende; Editing by David Goodman)
- Malaysia military source says missing jet veered to west |
- Ukraine appeals to West as Crimea turns to Russia |
- Malaysia air probe finds scant evidence of attack: sources |
- UPDATE 1-Missing Malaysian plane last seen at Strait of Malacca-source
- CIA accused of spying on U.S. Senate intelligence committee